EVAX earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -1.99. Updated 2026-07-23.
Evaxion Biotech (EVAX) Research Hub
Evaxion Biotech (EVAX) trades on NASDAQ, DK in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.13 USD (-4.86%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.99, market cap 0.02B. This hub links to the full technical, earnings and options research available for EVAX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, DK |
| Last close | 3.13 USD (-4.86%) |
| 52-week range | 2.8 USD – 3.79 USD |
| Trend regime | Range |
| 14-day RSI | 51.1 (Neutral) |
| Trailing P/E | -1.99 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for EVAX
Covered Call on EVAX: how it works, illustrative setup around the real 3.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EVAX: how it works, illustrative setup around the real 3.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EVAX: how it works, illustrative setup around the real 3.13 USD price, max profit/loss, breakeven and when to use it. Educational.
EVAX technical analysis: range, last 3.13 USD, RSI 51.1, 52w range 2.8 USD–3.79 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is EVAX in?
Evaxion Biotech (EVAX) is classified under Healthcare (Biotechnology), listed on NASDAQ, DK.
Is EVAX in an uptrend or downtrend?
As of 2026-09-11, EVAX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EVAX's trailing P/E ratio?
EVAX's trailing P/E is -1.99, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does EVAX next report earnings?
EVAX is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.01 USD.